CD160 [SEP] found in taxon
considered a proposed immune checkpoint inhibitor with anti-cancer activity alongside with anti- PD-1 antibodies. CD160 has also been proposed as a potential new target in cases of human pathological ocular and tumor neoangiogenesis that do not respond or become resistant to existing antiangiogenic drugs.
Related gene problems.
- TAR syndrome
- 1q21.1 deletion syndrome
- 1q21.1 duplication syndrome
See also.
- Cluster of differentiation
multimer. RNA blot analysis revealed CD160 mRNAs of 1.5 and 1.6 kb whose expression was highly restricted to circulating NK and T cells, spleen and small intestine. Within NK cells CD160 is expressed by CD56dimCD16+ cells whereas among circulating T cells its expression is mainly restricted to TCRgd bearing cells and to TCRab+CD8brightCD95+CD56+CD28-CD27-cells. In tissues, CD160 is expressed on all intestinal intraepithelial lymphocytes. CD160 shows a broad specificity for binding to both classical and nonclassical MHC class I molecules.
Clinical significance.
CD160 is a ligand for HVEM, and